This clinical trial is focused on studying treatments for cervical cancer that has returned or spread to other parts of the body after initial treatment. The study will compare a new treatment called Tisotumab Vedotin with other chemotherapy options chosen by the doctors involved in the study. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells. The purpose of the study is to see if Tisotumab Vedotin can improve the effectiveness of treatment for patients with this type of cancer.

Participants in the study will receive either Tisotumab Vedotin or one of the chemotherapy drugs, which may include Vinorelbine, Topotecan, Irinotecan, Pemetrexed, or Gemcitabine. These medications are given through an infusion, which means they are delivered directly into the bloodstream through a vein. The study will also involve the use of eye drops, such as Brimonidine Tartrate and Dexamethasone, which are used for different purposes related to eye health. The trial will monitor the overall survival of participants, which means the length of time they live after starting the treatment, as well as other factors like how long the cancer stays under control and any side effects experienced.

The study is designed to help researchers understand if Tisotumab Vedotin can provide better outcomes for patients with recurrent or metastatic cervical cancer compared to the standard chemotherapy options. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather important information about the effectiveness of the treatments being tested. The trial aims to provide valuable insights that could lead to improved treatment options for patients with this challenging condition.